Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pandemic

- PMLiVE

Moderna shares positive phase 3 results for mRNA influenza vaccine candidate

mRNA-1010 generated a strong immune response against all four WHO-recommended flu strains

- PMLiVE

US CDC recommends updated COVID-19 vaccines for autumn/winter season

Pfizer/BioNTech and Moderna’s updated vaccines will be available in the coming days

- PMLiVE

MIT researchers design more powerful RNA vaccines for COVID-19

The new type of RNA vaccine was shown to produce a stronger immune response at a lower dose

- PMLiVE

Moderna’s updated COVID-19 vaccine shows strong effect against BA.2.86 subvariant

The ‘highly mutated’ BA.2.86 subvariant is being closely monitored by global health authorities

- PMLiVE

NHS England to bring forward flu and COVID-19 vaccine programmes

The change follows an announcement on the risks presented by the new BA.2.86 COVID-19 variant

- PMLiVE

Pfizer and BioNTech’s XBB.1.5-adapted COVID-19 vaccine recommended by CHMP

Doses will be ready to ship immediately upon authorisation by the European Commission

- PMLiVE

US government awards $1.4bn for development of COVID-19 vaccines and therapeutics

The funding includes a contract with Regeneron for a next-generation antibody therapy

- PMLiVE

Novavax’s updated COVID-19 vaccine candidate shows promise against emerging subvariants

The protein-based vaccine generated immune responses against the fast-spreading ‘Eris’ strain

- PMLiVE

NHS to initiate flu vaccine roll-outs for children from September

The roll-outs are part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

World Health Organization classifies EG.5 as a COVID-19 ‘variant of interest’

The strain accounted for over 17% of COVID-19 cases between 17 and 23 July

- PMLiVE

JCVI announces advice for autumn COVID-19 booster vaccine eligibility

The Committee has advised offering the booster to those at high risk of serious disease

- PMLiVE

MHRA authorises HIPRA Human Health’s COVID-19 vaccine for use in UK

Bimervax is the ninth COVID-19 vaccine to be authorised by the UK medicines regulator

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links